Inpatient Double-Blind Placebo-Controlled Withdrawal Study of 3,4-Diaminopyridine Base (3,4-DAP) in Subjects with Known Lambert-Eaton Myasthenic Syndrome (LEMS) [JPC 3,4-DAPPER]

Administered By

Awarded By

Contributors

Start/End

  • November 16, 2018 - April 30, 2020